Hemoglobin News and Research

RSS

FDA agrees to Oncogenex' proposed amendment to Phase 3 AFFINITY protocol

OncoGenex Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has agreed to the Company's proposed amendment to the Phase 3 AFFINITY protocol and statistical analysis plan.

10 Jun 2015

Once-weekly Trulicity 0.75 mg shows promising results in Japanese patients with type 2 diabetes

Results from a new study of Japanese patients with type 2 diabetes showed once-weekly Trulicity 0.75 mg provided greater hemoglobin A1c (A1C) reduction compared to once-daily Victoza 0.9 mg after 52 weeks of treatment. Eli Lilly and Company will present these data at the 75th American Diabetes Association Scientific Sessions in Boston.

7 Jun 2015

Keeping blood sugar levels under control can help protect hearts from diabetes-related damage

Day in and day out, for years on end, millions of people with diabetes prick their fingers to test their blood sugar level. And many may wonder if all the careful eating, exercise and medication it takes to keep those levels under control is really worth it.

4 Jun 2015

Apatorsen added to first-line chemotherapy benefits metastatic bladder cancer patients

OncoGenex Pharmaceuticals, Inc. announced that results from an exploratory analysis of the Phase 2 Borealis-1 trial showed that metastatic bladder cancer patients with poor prognostic features benefited from apatorsen 600mg added to first-line chemotherapy compared to chemotherapy alone.

2 Jun 2015

Pharmacyclics's Phase III RESONATE™ trial shows adherence to 420mg dose of IMBRUVICA improves outcomes in CLL patients

Pharmacyclics LLC today highlighted results from a sub-analysis of the Phase III RESONATE™ (PCYC-1112) trial, which found that previously-treated patients with chronic lymphocytic leukemia (CLL) who adhered to the recommended 420 mg dose of IMBRUVICA® (ibrutinib) experienced improved progression-free survival (PFS; the primary endpoint) as assessed by an Independent Review Committee (IRC), compared to patients who took lower doses or missed doses, regardless of high-risk genetic factors.

1 Jun 2015

Pharmacyclics’ Ibrutinib Phase Ib/II data show ibrutinib may be safe and effective in patients with cGVHD

Pharmacyclics LLC today announced interim results from the ongoing Phase Ib/II PCYC-1129 study suggesting that ibrutinib (IMBRUVICA) may be a safe and effective treatment for patients with chronic graft-versus-host-disease (cGVHD) who were either refractory to steroid treatment or were steroid-dependent.

1 Jun 2015

Phase III HELIOS trial results show ibrutinib combination therapy improves outcomes in CLL/SLL patients

Today, Pharmacyclics LLC announced the results of the Phase III HELIOS trial (CLL3001), which found that patients with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who received ibrutinib (IMBRUVICA) in combination with bendamustine and rituximab (BR) experienced an 80% reduction in the risk of progression or death compared to patients receiving placebo in combination with BR.

1 Jun 2015

OncoGenex's Phase 3 SYNERGY trial shows survival benefits of custirsen therapy in CRPC patients with poor prognosis

OncoGenex Pharmaceuticals, Inc. announced today that results from a retrospective analysis of the Phase 3 SYNERGY trial showed a benefit with custirsen therapy in men with metastatic castrate-resistant prostate cancer (CRPC) who had a poor prognosis.

1 Jun 2015

Functional foods help reduce obesity, control diabetes

The so called functional foods such as cactus pads, chia and soybean, when included in a balanced diet, help reduce obesity and control diabetes, says Nimbe Torres y Torres, from the Institute of Biomedical Research at the National Autonomous University of Mexico.

28 May 2015

Carbon monoxide may actually protect the brain from damage after subarachnoid hemorrhage

Carbon monoxide is known by many as a poisonous gas that causes brain injury and other neurological symptoms, including memory loss and confusion. But a new study led by investigators at Beth Israel Deaconess Medical Center suggests the opposite may be true: When administered in small, carefully controlled amounts, carbon monoxide may actually protect the brain from damage following subarachnoid hemorrhage, a devastating stroke that results from bleeding in the brain.

27 May 2015

Treatment outcomes in type 1 diabetes could be improved across all age groups

In a sweeping analysis assessing the current state of diabetes treatment in the U.S., T1D Exchange researchers conclude that there remains considerable room for improving treatment outcomes in type 1 diabetes across all age groups, but especially for adolescents and young adults.

22 May 2015

Shiftworkers more likely to develop metabolic disorders

Shiftwork is an occupational health risk of growing significance because it is becoming more common and because of its potential influence on health outcomes, possibly increasing health differences between workers of higher vs lower socioeconomic status.

18 May 2015

EKF highlighting its expanding range of liquid stable clinical chemistry reagents at Hospitalar 2015

EKF Diagnostics will be highlighting its expanding Stanbio central laboratory clinical chemistry range at Hospitalar, 19–22 May, Sao Paulo, Brazil.

From EKF Diagnostics 14 May 2015

AMC Health to collaborate with URAC on national telehealth standards development initiative

AMC Health, a leading provider of 'real-time' patient management solutions has announced that it will collaborate with URAC on its national telehealth standards development initiative.

5 May 2015

Researchers reveal potential mode of drug resistance in malaria parasites

Scientists have uncovered a potential mode of parasite drug resistance in malaria infection, according to a report published in The Journal of Experimental Medicine.

5 May 2015

Sangamo BioSciences to present data on ZFP Therapeutic platform at ASGCT meeting

Sangamo BioSciences, Inc. announced that data from clinical, preclinical and research-stage programs focused on the development of ZFP Therapeutics will be presented at the 18th Annual Meeting of the American Society of Gene and Cell Therapy

29 Apr 2015

Church-based education program improves diet, exercise habits among Latino adults with diabetes

Latino adults with diabetes who participated in a church-based education program reported eating less high-fat food and exercising more following a trial intervention program run by researchers from University of Chicago's Department of Medicine.

29 Apr 2015

Adjustable gastric band surgery, weight management program offer similar benefits in diabetes patients

Weight loss is never easy, but it's important for overweight people with type 2 diabetes seeking to control their blood sugar levels and optimize their health. A small clinical trial among such patients led by Joslin Diabetes Center and Brigham and Women's Hospital researchers now has shown that two approaches--adjustable gastric band surgery and an intensive group-based medical diabetes and weight management program--achieved similar improvements in controlling blood sugar levels after one year.

29 Apr 2015

National survey shows that most women don't know risks or symptoms of stroke

A national survey released today by The Ohio State University Wexner Medical Center shows that most women don't know the risks or symptoms females face when it comes to having a stroke.

28 Apr 2015

Combination therapy effective in HCV patients with advanced cirrhosis and post-transplant recurrence

Phase 3 results presented today at The International Liver Congress 2015 show that a combination of daclatasvir (DCV), sofosbuvir (SOF) and ribavirin (RBV) for 12 weeks was effective and well tolerated amongst patients with hepatitis C virus (HCV) infection with advanced cirrhosis and post-transplant recurrence.

27 Apr 2015

Hemoglobin News and Research

FDA agrees to Oncogenex' proposed amendment to Phase 3 AFFINITY protocol

Once-weekly Trulicity 0.75 mg shows promising results in Japanese patients with type 2 diabetes

Keeping blood sugar levels under control can help protect hearts from diabetes-related damage

Apatorsen added to first-line chemotherapy benefits metastatic bladder cancer patients

Pharmacyclics's Phase III RESONATE™ trial shows adherence to 420mg dose of IMBRUVICA improves outcomes in CLL patients

Pharmacyclics’ Ibrutinib Phase Ib/II data show ibrutinib may be safe and effective in patients with cGVHD

Phase III HELIOS trial results show ibrutinib combination therapy improves outcomes in CLL/SLL patients

OncoGenex's Phase 3 SYNERGY trial shows survival benefits of custirsen therapy in CRPC patients with poor prognosis

Functional foods help reduce obesity, control diabetes

Carbon monoxide may actually protect the brain from damage after subarachnoid hemorrhage

Treatment outcomes in type 1 diabetes could be improved across all age groups

Shiftworkers more likely to develop metabolic disorders

EKF highlighting its expanding range of liquid stable clinical chemistry reagents at Hospitalar 2015

AMC Health to collaborate with URAC on national telehealth standards development initiative

Researchers reveal potential mode of drug resistance in malaria parasites

Sangamo BioSciences to present data on ZFP Therapeutic platform at ASGCT meeting

Church-based education program improves diet, exercise habits among Latino adults with diabetes

Adjustable gastric band surgery, weight management program offer similar benefits in diabetes patients

National survey shows that most women don't know risks or symptoms of stroke

Combination therapy effective in HCV patients with advanced cirrhosis and post-transplant recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News